XSHG688321
Market cap958mUSD
Jan 10, Last price
16.73CNY
1D
-0.12%
1Q
-10.73%
IPO
-79.75%
Name
Shenzhen Chipscreen Biosciences Co Ltd
Chart & Performance
P/E
76.80
P/S
13.23
EPS
0.22
Div Yield, %
0.27%
Shrs. gr., 5y
2.56%
Rev. gr., 5y
28.42%
Revenues
516m
-2.67%
Net income
89m
+593.18%
CFO
-143m
L
Earnings
Apr 18, 2025
Profile
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines that are in various research phase of the specific global intellectual property protection in three areas, such as cancer, metabolic diseases, and autoimmune diseases. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is based in Shenzhen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 515,786 -2.67% | 529,939 23.11% | ||||||
Cost of revenue | 484,956 | 466,905 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | 30,830 | 63,035 | ||||||
NOPBT Margin | 5.98% | 11.89% | ||||||
Operating Taxes | 47,831 | 2,341 | ||||||
Tax Rate | 155.15% | 3.71% | ||||||
NOPAT | (17,002) | 60,694 | ||||||
Net income | 88,839 593.18% | 12,816 -41.63% | ||||||
Dividends | (18,743) | |||||||
Dividend yield | 0.21% | |||||||
Proceeds from repurchase of equity | (1) | |||||||
BB yield | 0.00% | |||||||
| Debt | ||||||||
Debt current | 132,956 | 210,780 | ||||||
Long-term debt | 919,295 | 600,596 | ||||||
Deferred revenue | 77,040 | 86,959 | ||||||
Other long-term liabilities | 139,559 | 93,290 | ||||||
Net debt | 150,349 | 11,715 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (143,211) | 43,296 | ||||||
CAPEX | (229,029) | |||||||
Cash from investing activities | (389,069) | |||||||
Cash from financing activities | 382,617 | 861,288 | ||||||
FCF | 48,921 | (287,141) | ||||||
| Balance | ||||||||
Cash | 849,676 | 799,661 | ||||||
Long term investments | 52,227 | |||||||
Excess cash | 876,113 | 773,164 | ||||||
Stockholders' equity | 582,338 | 580,858 | ||||||
Invested Capital | 2,339,614 | 1,958,296 | ||||||
ROIC | 3.69% | |||||||
ROCE | 1.05% | 2.48% | ||||||
| EV | ||||||||
Common stock shares outstanding | 408,265 | 406,970 | ||||||
Price | 21.95 -0.14% | 21.98 -37.22% | ||||||
Market cap | 8,961,424 0.18% | 8,945,212 -37.63% | ||||||
EV | 9,111,773 | 9,017,161 | ||||||
EBITDA | 76,452 | 101,759 | ||||||
EV/EBITDA | 119.18 | 88.61 | ||||||
Interest | 34,881 | 20,133 | ||||||
Interest/NOPBT | 113.14% | 31.94% | ||||||